Mutya Harsch insider trades: VYNE Therapeutics (VYNE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mutya reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 20, 2023 | VYNE | ↑ Buy | 10,000 | $2.50 | $25K | Direct | Mar 22, 2023 (2d) |
| Jul 1, 2019 | FOMX | ↓ Sell | 639 | $2.35 | $2K | Direct | Jul 3, 2019 (2d) |
| Apr 1, 2019 | FOMX | ↓ Sell | 2,519 | $3.75 | $9K | Direct | Apr 3, 2019 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Mutya Harsch's insider trades
Mutya Harsch is Chief Legal Officer and GC at VYNE Therapeutics (VYNE). Since Apr 1, 2019, Mutya has reported 1 open-market purchase worth $25K and 2 sales worth $11K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include shares withheld for taxes (28 filings), grants and awards (19 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VYNE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.